Rational design of HIV vaccines and microbicides: report of the EUROPRISE network annual conference 2010
- PDF / 293,150 Bytes
- 12 Pages / 595.276 x 793.701 pts Page_size
- 26 Downloads / 150 Views
REVIEW
Open Access
Rational design of HIV vaccines and microbicides: report of the EUROPRISE network annual conference 2010 Sarah Brinckmann1, Kelly da Costa2, Marit J van Gils3, David Hallengärd4, Katja Klein2, Luisa Madeira5, Lara Mainetti6,7, Paolo Palma8, Katharina Raue9, David Reinhart10, Marc Reudelsterz11, Nicolas Ruffin4, Janna Seifried11, Katrein Schäfer12, Enas Sheik-Khalil13, Annette Sköld14, Hannes Uchtenhagen14, Nicolas Vabret15, Serena Ziglio16, Gabriella Scarlatti6, Robin Shattock2, Britta Wahren4* and Frances Gotch17
Abstract Novel, exciting intervention strategies to prevent infection with HIV have been tested in the past year, and the field is rapidly evolving. EUROPRISE is a network of excellence sponsored by the European Commission and concerned with a wide range of activities including integrated developmental research on HIV vaccines and microbicides from discovery to early clinical trials. A central and timely theme of the network is the development of the unique concept of co-usage of vaccines and microbicides. This review, prepared by the PhD students of the network captures much of the research ongoing between the partners. The network is in its 5th year and involves over 50 institutions from 13 European countries together with 3 industrial partners; GSK, Novartis and SanofiPasteur. EUROPRISE is involved in 31 separate world-wide trials of Vaccines and Microbicides including 6 in African countries (Tanzania, Mozambique, South Africa, Kenya, Malawi, Rwanda), and is directly supporting clinical trials including MABGEL, a gp140-hsp70 conjugate trial and HIVIS, vaccine trials in Europe and Africa. Introduction It seems clear that the EUROPRISE-sponsored studies reported herein are evolving within a dynamic HIV prevention landscape. Participants at the EUROPRISE Network Annual Conference discussed how EUROPRISE can best contribute to and facilitate the Global Enterprise Plan described by Alan Bernstein, executive director of the Global HIV vaccine Enterprise, and furthermore how promising data from the Thai RV-144 vaccine trial [1], the HIVIS vaccine trials [2], the Caprisa 004 tenofovir microbicide trial [3], and recent ARTPrEP (antiretrovirals for preexposure treatment) trials should influence our thinking and maximize research momentum. Such novel interventions should be considered along with more established prevention measures such as circumcision, condom use and diminishing transmission of HIV through the use of effective ART. * Correspondence: [email protected] 4 Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Nobels väg, Stockholm, 171 77, Sweden Full list of author information is available at the end of the article
It was considered that novel prevention combinations are desirable and that members of the EUROPRISE consortium were particularly well placed to undertake studies investigating such combined effects. Possible combinations suggested were: • The use of vaccines in circumcised men to further reduce transmission. • The combined use of oral PrEP a
Data Loading...
